Chief Medical Officer, bluebird bio, Inc.
Dave Davidson, M.D. has served as CMO at bluebird bio since 2012. Previously, he conducted clinical research at Genzyme and GelTex. He completed clinical and research fellowships in infectious diseases at the Harvard Longwood Combined Infectious Diseases Program, and completed an...
Read More →TF
Dean, Provost and Executive Deputy Chancellor, University of Massachusetts Medical School
Provost & Executive Deputy Chancellor, Celia & Isaac Haidak Professor of Medical Education & Dean of the UMass Medical School. Internationally known pioneer in human gene therapy, He is currently investigating the use of gene therapy for genetic diseases, including alpha-1 antitrypsin...
Read More → 
Biologist/CMC Reviewer, Gene Therapy Branch, OTAT, CBER, FDA
Mike has been a CMC Reviewer in the Gene Therapy Branch since 2004. Gene Therapies are a diverse group of new technologies that include genetically modified viruses and cells. Mike’s recent accomplishments include serving as BLA Chair for a genetically modified autologous T-cell...
Read More →DJ
Chief Scientific Officer, Co-Founder, Precision Biosciences
Derek Jantz, PhD co-founded genome editing company Precision BioSciences in 2006 and serves as Chief Scientific Officer. He has a BA in biology from the University of Colorado, a PhD in Biophysics from the Johns Hopkins University School of Medicine, and completed a postdoctoral fellowship...
Read More → 
Director, Center for Biologics Evaluation and Research, FDA
Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching...
Read More →
